In his 25 years of practice, Richard C. Pettus has handled over 100 patent, trademark and trade secret litigations involving a wide range of technologies, including pharmaceuticals, medical devices, computer software and hardware, semiconductors, polymers, “green” technology, energy and industrial equipment, fiber optics, chemical processes and consumer products.
Throughout his career, Rich has helped his clients achieve their business and litigation goals through creative and dynamic litigation strategies. He has been recognized by clients, peers and in industry publications such as LMG Life Sciences and IAM 1000 as a “standout” and “adroit pharmaceutical litigator” who is a “real expert on pharmaceutical patent issues” that “thinks outside the box,” and “walks through every detail” with a “meticulous” and “very collaborative approach,” but “never loses sight of the bigger picture.”
In the biopharmaceutical and ANDA Hatch-Waxman arena, Rich has served as lead counsel at both the trial and on appellate levels for companies such as Teva Pharmaceuticals, Alembic, Baxter Healthcare, BioMarin Pharmaceutical, Boehringer-Ingelheim, B. Braun Medical Inc., Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, GlaxoSmithKline, Glenmark Pharmaceuticals, and Sanofi, in matters involving small and large drug molecules, their polymorphic, enantiomeric and pegylated forms, combinations, uses and formulations as well as devices for injectable, oral and inhaled drug delivery, DNA constructs, vaccines, manufacturing processes and diagnostic kits.
Rich also counsels Fortune 250 and emerging technology companies, individuals and investors on intellectual property management and other proprietary technology related issues, including strategies for patent due diligence, pre-litigation investigations, licensing, antitrust, life cycle management, and patent and trademark prosecution related issues. Prior to joining Greenberg Traurig, Rich served as the Deputy Intellectual Property Practice Group Leader, Member of the Hiring Committee, and Co-Head of the Pharmaceutical, Biotechnology and Medical Device Strategic Initiative at one of his former firms.
- Patent litigation
- ANDA Hatch-Waxman litigation
- General IP counseling, licensing, due diligence and opinions
- Global energy and infrastructure